Health Care Access & Coverage
Covering the Cure: Access and Payment for High-Cost Cell and Gene Therapies
A Conversation with Stacie Dusetzina, PhD, Titilope Fasipe, MD, PhD, Jarrod Henshaw, and Aaron Kesselheim, MD, JD, moderated by David Grande, MD, MPA
New cell and gene therapies create the promise of curing debilitating conditions that were previously thought to be incurable. These highly specialized and highly personalized therapies come with price tags in the millions of dollars for a single treatment. For example, new treatments could cure sickle cell disease for some of the 100,000 Americans who live with the disease. However, the two approved treatments are between $2 and 3 million per dose. And projecting demand is challenging: some patients may be reluctant to undergo new treatment. How are public and private insurers thinking about paying for these therapies and how should they prepare for future breakthroughs? LDI’s expert panel will unpack the current landscape and options for increasing access to these treatments while creating sustainable payment strategies.
Speakers
Stacie Dusetzina, PhD
Professor, Health Policy and Ingram Professor of Cancer Research, Vanderbilt University Medical Center
Titilope Fasipe, MD, PhD
Co-Director, Sickle Cell Program; Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
Jarrod Henshaw
Senior Vice President, Chief Innovation and Supply Chain Officer, Prime Therapeutics
Aaron Kesselheim, MD, JD
Professor, Medicine, Harvard Medical School
